Skip to content

2026 Diamond Insight Survey

Thank you for participating in this important annual initiative.

This survey gathers insights from NCODA members across practice settings to understand current challenges, emerging trends, and areas needing additional support — especially in communication, access, innovation, and care delivery.

Your responses will help:

  • Shape NCODA’s strategic programs and advocacy
  • Inform future collaboration with our Diamond Pharmaceutical Partners
  • Guide industry in delivering meaningful, practice-aligned support

The survey has up to 32 questions and should take approximately 20 minutes to complete.

Your responses are confidential and will be aggregated for reporting purposes.

Let’s get started!
1.What is your primary role on the Medically Integrated Oncology Care Team?
(Select one that best describes your primary function)
2.Which setting best describes your practice?
(Select the one that best aligns with your institution)
Section 1: Communication & Education in a Rapidly Evolving Oncology Landscape
Oncology care continues to evolve rapidly, from biomarker-driven treatments to new modalities and care delivery models. We'd like to understand how your team stays up to date and how communication with the pharmaceutical industry supports or challenges your ability to deliver optimal care.
3.How do you typically learn about new oncology treatment options, FDA approvals, or clinical updates? (Select your top 5 sources of information)
4.Which types of communications from the pharmaceutical industry do you find most valuable? (Rate each content type from least to most valuable)
Least Valuable
Valuable
Most Valuable
Unbranded disease state education
Medical Affairs engagement (e.g., MSLs)
Reimbursement or access support (e.g., Field Access Specialists)
Branded education (specific drug updates)
Information about Patient Assistance Programs or Specialty Pharmacy Distribution Networks
Real World Data / HEOR
5.What is your preferred method of delivery for industry communication? (Rank from least preferred to most preferred)
Least Preferred
Preferred
Most Preferred
Live in-person meetings or events (e.g., office visit, dinner program)
Virtual meetings (e.g., Zoom with MSL, webinars)
Email communications
On-demand content (videos, slide decks, e-learnings)
Peer-to-peer discussions or collaborative panels
6.What topics would you like more education or support around? (Select your top 5 priorities)
Section 2: IRA Patient Affordability Provisions — MOOP & M3P
Recent changes through the Inflation Reduction Act (IRA) — including the Medicare out-of-pocket (MOOP) cap and the Medicare Prescription Payment Plan (M3P) — were designed to improve patient affordability. We want to understand how these changes are affecting your practice, your patients, and the support you need to implement them effectively.
7.How would you characterize the impact of the Medicare MOOP (maximum out-of-pocket cap) on patient care so far? (Please Agree or Disagree with each statement below)
Agree
Disagree
N/A or Unknown
Has significantly reduced financial distress for Medicare patients
Has improved adherence or reduced treatment abandonment
Has improved the ability to initiate or maintain oral oncolytics
Has made little difference so far due to limited awareness
Too early to tell / not enough data yet to assess impact
8.Is your practice currently educating patients about the Medicare Prescription Payment Plan (M3P)?
9.What challenges has your practice experienced (or do you anticipate) related to M3P enrollment or implementation? (Select all that apply)
10.Which roles in your practice are primarily responsible for discussing IRA affordability provisions with patients? (Select all that apply)
11.What additional resources or support would help your team implement MOOP/M3P/Medicare Extra Help (LIS) more effectively? (Ranking most to least helpful)
Not Helpful or N/A
Slightly Helpful
Helpful
Extremely Helpful
Easy-to-understand educational materials for patients
Staff training or cheat sheets on M3P workflows
Manufacturer reimbursement or access team support
EHR-integrated tools or reminders
Patient stories or case examples
Section 3: Understanding & Preparing for IRA Price Negotiation and Effectuation
The IRA's drug pricing provisions — including the establishment of a Maximum Fair Price (MFP) and the requirement for manufacturers to "effectuate" those prices within Medicare — are changing how oncology therapies are reimbursed and accessed. We want to understand how these policies are being perceived and what support your practice needs moving forward.
12.How familiar are you with the IRA-related concepts of MFP and price effectuation?
13.How do you anticipate MFP and effectuation policies will affect your practice operations? (Select all that apply)
14.What impact — if any — do you anticipate MFP and effectuation may have on patient access or care continuity? (Select all that apply)
15.What is your practice currently doing to prepare for IRA-related price negotiations or changes in access? (Select all that apply)
16.What type of support would be most helpful to you as more therapies become subject to MFP pricing and effectuation? (Please rate from not helpful to very helpful)
Not Helpful
Slightly Helpful
Helpful
Extremely Helpful
Case studies from early-effectuated therapies (e.g., Ibrutinib)
Updates and timelines from manufacturers
Operational guidance for pharmacy and billing teams
Education for clinical staff on implications for prescribing
NCODA-driven resources or explainer sessions
17.Do you have any questions or concerns about these policies that NCODA or manufacturers could help address?
Section 4: Precision Medicine in Practice — Testing & Operational Challenges
The use of precision medicine continues to expand rapidly in oncology care. From choosing the right testing modality (e.g., NGS, RNA vs DNA, tumor vs blood) to interpreting results and operationalizing timely treatment, there are still significant hurdles. We want to understand what's working and what support is needed.
18.What are the biggest barriers your practice faces when implementing biomarker or genomic testing? (Select all that apply)
19.How confident is your clinical team in knowing which type of test to order for specific clinical scenarios?
20.What is your average turnaround time for receiving test results? (Select one that best reflects your experience:)
21.Does your team feel they have adequate education on interpreting precision medicine results and applying them to treatment decisions?
22.What types of educational or operational support would be helpful in supporting your ability to deliver precision medicine?
Not at all helpful
Somewhat helpful
Extremely helpful
Quick reference guide for test ordering by disease state
Case-based education or peer-to-peer discussions
Access to interpretation support (i.e., molecular tumor board)
Tools that integrate testing guidance into EHR workflows
Reimbursement/Appeal Support
Patient Education Resources
Section 5: Bispecifics in Practice — Support Needs & Implementation Readiness
Bispecific antibody therapies represent an important and growing class of immunotherapies. NCODA offers several resources to support implementation, including our Immunotherapy Hub and the Practice Matching Liaison Program. We want to understand where additional support is needed to ensure successful integration of bispecifics into patient care.
23.Is your practice currently administering or preparing to administer bispecific T-cell engager therapies in the outpatient setting?
24.Which areas remain most challenging when implementing step-up/ramp-up bispecific dosing in your practice? (Select up to 3)
25.Have you utilized NCODA's Immunotherapy Hub or the Practice Matching Liaison Program for bispecific support? (Select all that apply:)
26.What additional resources or support would help your team implement bispecific therapies more effectively? (Select your top 3:)
Section 6: Limited Distribution Drugs & the OOLD Framework
Many oncology therapies are now distributed through Limited Distribution Drug (LDD) networks. NCODA developed the Oncology Optimized Limited Distribution (OOLD) framework to promote models that prioritize patient access, provider control, and clinical coordination. We'd like to better understand how these distribution models are impacting practice workflows and patient care.
27.How familiar are you with the Oncology Optimized Limited Distribution (OOLD) model?
28.What challenges has your practice experienced with current distribution models where patients are required to fill prescriptions outside the clinic (i.e., PBM-mandated)? (Select up to 3)
29.What educational resources would help your team better manage patients on OOLD therapies? (Select your top 3)
30.Does your practice currently measure or track patient-level impact of therapies filled inside vs. outside the practice? (Check all metrics your practice tracks, for each setting)
Filled inside practice
Filled outside practice
Time from prescription to medication start (time-to-fill)
Patient adherence over time
Treatment persistence
Delays due to external pharmacy or insurance
We do not currently track patient-specific metrics
Unsure
31.What support — from NCODA or industry — would be most helpful in improving your workflows and patient outcomes as it relates to OOLD?
32.What is the biggest challenge your practice is currently facing in delivering high-quality oncology care?
Thank you for taking the time to complete the 2026 NCODA Diamond Insights Survey.

Your insights directly inform how NCODA shapes its resources, advocacy, and educational initiatives — and they help our Diamond Partners better support practices like yours.

Together, we can elevate oncology care by ensuring that patient-centered, medically integrated models remain at the forefront of innovation, access, and outcomes.